Rosuvastatin belongs to a class of medications commonly called "statins" which are
medications given for high low density lipoprotein (LDL) 'bad' cholesterol to prevent
atherosclerosis (hardening of blood vessels) and lower risk of heart attacks and other
circulation problems. Recent studies in the general non-HIV infected population have shown
that the beneficial effect of statins in preventing circulation problems is larger than would
be expected from lowering of LDL-cholesterol alone. It has been suggested that the additional
beneficial effect of statins may be due to the anti-inflammatory effect of statins.
The risk of heart attacks and other circulation problems may be high in HIV infected
individuals. This may be due to the inflammatory stress effects of HIV. The main purpose of
the study is to see if rosuvastatin will have a beneficial effect on the circulatory system
in HIV infected individuals even in those who do not have high LDL cholesterol levels.
Therefore, in HIV-infected individuals with normal or low LDL cholesterol levels but with
evidence of low HDL cholesterol levels which may be a sign of low grade inflammation, the
study will look at whether 3 months of rosuvastatin will lead to improvement in brachial
artery flow-mediated dilatation (FMD), a marker of early atherosclerosis (hardening of the
blood vessels).